Literature DB >> 2275526

Serum IgG subclass antibody responses in children vaccinated with influenza virus antigens by live attenuated or inactivated vaccines.

N M Garcon1, J Groothuis, S Brown, B Lauer, P Pietrobon, H R Six.   

Abstract

To ascertain whether live attenuated or inactivated vaccines can be considered equivalent, we examined the primary antibody response of children following vaccination with influenza virus antigens in three different formulations. Nine children received cold recombinant vaccine (CRV) containing A/Korea/82 (H3N2) and A/Dunedin/83 (H1N1) variants. Eight of these children responded to HA of the H3N2 subtype and the major portion of the elicited antibody was in the IgG1 subclass. Antibody of low titer in the IgG2 and IgG3 subclasses was detected in two and six serum specimens, respectively. Six of the nine children administered with CRV responded to the H1 antigen and only IgG1 antibody was detected. Serum specimens from eight children less than one year of age (5 less than 6 months of age) who had developed an antibody response to trivalent inactivated vaccine (TIV) vaccination were examined. High levels of IgG1 antibody to purified H3 were detected in all eight children. Low titers of antibody in IgG2 and IgG3 subclasses were detected in two and five children, respectively. Antibody responses to purified H1 showed a similar subclass distribution. In order to examine secondary response, eight children primed by immunization with TIV vaccine were subsequently given a single booster dose of purified hemagglutinin (HA) conjugated to diphtheria toxoid (HA-D). In 6/8 specimens antibody rises were detected to purified H3 and H1 antigens. Prior to the HA-D immunization, low levels of HA specific IgG1 antibody were detected in all serum specimens and vaccine induced responses were primarily of the IgG1 subclass.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2275526     DOI: 10.1016/0166-3542(90)90048-c

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  4 in total

1.  Identification of a novel antigen-presenting cell population modulating antiinfluenza type 2 immunity.

Authors:  Jae-Kwang Yoo; Carole L Galligan; Carl Virtanen; Eleanor N Fish
Journal:  J Exp Med       Date:  2010-06-14       Impact factor: 14.307

2.  Kinetics of antibody response to influenza vaccination in renal transplant recipients.

Authors:  Shivaprakash Gangappa; Jens Wrammert; David Wang; Zhu-Nan Li; Justine S Liepkalns; Weiping Cao; Jufu Chen; Min Z Levine; James Stevens; Suryaprakash Sambhara; Beth Begley; Aneesh Mehta; Thomas C Pearson; Rafi Ahmed; Christian P Larsen
Journal:  Transpl Immunol       Date:  2019-01-18       Impact factor: 1.708

3.  Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011-2012 influenza vaccine season.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Nicholas V Mendez; Ana Marie Landin; Bonnie B Blomberg
Journal:  Immun Ageing       Date:  2013-04-22       Impact factor: 6.400

4.  Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production.

Authors:  Can Li; Kelvin K W To; Anna J X Zhang; Andrew C Y Lee; Houshun Zhu; Winger W N Mak; Ivan F N Hung; Kwok-Yung Yuen
Journal:  Front Immunol       Date:  2018-10-12       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.